- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Waltham Today
By the People, for the People
Cogent Biosciences Nears Triple Approval for Lead Drug
Biotech firm's bezuclastinib shows promise in GIST and systemic mastocytosis trials
Published on Mar. 4, 2026
Got story updates? Submit your updates here. ›
Cogent Biosciences, a biotech company based in Waltham, Massachusetts, is nearing regulatory approvals for its lead drug bezuclastinib in the treatment of gastrointestinal stromal tumors (GIST) and systemic mastocytosis. The positive trial data and the company's $900 million cash position have analysts bullish on the stock.
Why it matters
Cogent's potential triple approval for bezuclastinib would be a significant milestone for the company, providing it with multiple revenue streams in rare disease markets. The drug's success could also validate Cogent's broader pipeline and solidify its position as a rising player in the biotech industry.
The details
Cogent Biosciences is seeking approvals for bezuclastinib in the treatment of GIST and systemic mastocytosis, two rare and difficult-to-treat conditions. The company has reported positive data from late-stage clinical trials for the drug, showing promising efficacy and safety profiles. With a strong cash position, Cogent is well-positioned to navigate the regulatory process and commercialize bezuclastinib if approved.
- Cogent Biosciences reported positive clinical trial data for bezuclastinib in November 2025.
- The company is currently seeking regulatory approvals for the drug in the treatment of GIST and systemic mastocytosis.
The players
Cogent Biosciences, Inc.
A biotech company based in Waltham, Massachusetts that is developing novel therapies for rare diseases, including gastrointestinal stromal tumors (GIST) and systemic mastocytosis.
bezuclastinib
Cogent Biosciences' lead drug candidate that is being evaluated for the treatment of GIST and systemic mastocytosis.
What they’re saying
“If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth?”
— Edmund Ingham, Biotech Consultant (Seeking Alpha)
What’s next
Cogent Biosciences is currently seeking regulatory approvals for bezuclastinib in the treatment of GIST and systemic mastocytosis. The company is expected to provide updates on the progress of these approval processes in the coming months.
The takeaway
Cogent Biosciences' potential triple approval for its lead drug bezuclastinib would be a significant achievement for the company, providing it with multiple revenue streams in rare disease markets and validating its broader pipeline. The company's strong cash position and positive clinical trial data have analysts bullish on its prospects.
